Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) have been assigned a consensus recommendation of "Hold" from the nineteen research firms that are presently covering the firm, MarketBeat reports. Three research analysts have rated the stock with a sell recommendation, four have assigned a hold recommendation and eleven have given a buy recommendation to the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $156.50.
CRSP has been the topic of a number of recent research reports. Stifel Nicolaus increased their target price on CRISPR Therapeutics from $91.00 to $145.00 and gave the stock a "positive" rating in a research note on Monday, December 7th. They noted that the move was a valuation call. Raymond James reissued a "sell" rating on shares of CRISPR Therapeutics in a research report on Friday, October 30th. Canaccord Genuity increased their price target on CRISPR Therapeutics from $120.00 to $151.00 and gave the stock a "buy" rating in a research report on Monday, December 7th. Piper Sandler increased their price target on CRISPR Therapeutics from $107.00 to $180.00 and gave the stock an "overweight" rating in a research report on Thursday, December 10th. Finally, Truist increased their price target on CRISPR Therapeutics from $170.00 to $210.00 in a research report on Tuesday, January 12th.
Shares of NASDAQ CRSP opened at $125.69 on Friday. The firm has a market cap of $9.48 billion, a P/E ratio of -38.56 and a beta of 2.37. CRISPR Therapeutics has a 1-year low of $32.30 and a 1-year high of $220.20. The business's 50 day moving average is $171.54 and its 200-day moving average is $125.20.
CRISPR Therapeutics (NASDAQ:CRSP) last announced its earnings results on Monday, February 15th. The company reported ($1.50) earnings per share for the quarter, missing the Zacks' consensus estimate of ($1.27) by ($0.23). The firm had revenue of $0.37 million for the quarter, compared to the consensus estimate of $4.69 million. CRISPR Therapeutics had a negative return on equity of 20.72% and a negative net margin of 273.10%. On average, research analysts predict that CRISPR Therapeutics will post -4.97 earnings per share for the current fiscal year.
In related news, Director Bradley J. Phd Bolzon sold 7,648 shares of the firm's stock in a transaction on Wednesday, December 16th. The stock was sold at an average price of $148.95, for a total transaction of $1,139,169.60. Following the sale, the director now owns 6,734 shares of the company's stock, valued at approximately $1,003,029.30. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Bradley J. Phd Bolzon sold 171,004 shares of the firm's stock in a transaction on Monday, December 7th. The shares were sold at an average price of $154.53, for a total value of $26,425,248.12. Following the sale, the director now directly owns 40,648 shares in the company, valued at approximately $6,281,335.44. The disclosure for this sale can be found here. In the last three months, insiders have sold 427,703 shares of company stock worth $66,444,533. 17.10% of the stock is currently owned by company insiders.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Trustcore Financial Services LLC bought a new position in CRISPR Therapeutics during the 4th quarter worth $31,000. Summit X LLC bought a new position in CRISPR Therapeutics during the 3rd quarter worth $34,000. Parallel Advisors LLC bought a new position in CRISPR Therapeutics during the 4th quarter worth $38,000. Capital Advisory Group Advisory Services LLC raised its position in CRISPR Therapeutics by 300.0% during the 4th quarter. Capital Advisory Group Advisory Services LLC now owns 248 shares of the company's stock worth $38,000 after purchasing an additional 186 shares during the last quarter. Finally, Gemmer Asset Management LLC raised its position in CRISPR Therapeutics by 438.0% during the 4th quarter. Gemmer Asset Management LLC now owns 269 shares of the company's stock worth $41,000 after purchasing an additional 219 shares during the last quarter. 66.43% of the stock is currently owned by institutional investors.
About CRISPR Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious human diseases. It develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), a gene editing technology that allows for precise directed changes to genomic DNA.
Read More: Moving Average Convergence Divergence (MACD)
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Before you consider CRISPR Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CRISPR Therapeutics wasn't on the list.
While CRISPR Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The 5 Stocks Here